It has been suggested that interleukin-33 (IL-33) plays an important role in the pathogenesis of asthma through a variety of pathways, but its role in airways fibrosis in asthma has not been fully elucidated. In the present study we evaluated changes in the expression of extracellular matrix proteins (ECMs) as well as matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) in an IL-33-induced, antigen-independent murine surrogate of asthma as well as a conventional surrogate employing pernasal challenge of mice previously sensitized to produce an IgE response to ovalbumin (OVA). In addition, in in vitro experiments we explored the direct effects of IL-33 on the proliferation and function of murine fibroblasts. Per-nasal administration of IL-33 alone was sufficient to induce airways deposition of ECMs, including collagens I, III, V and fibronectin, to a degree comparable with that observed in the OVA-sensitized and challenged mice. These changes were associated with a local imbalance between the expression of extracellular MMPs and TIMPs. Per-nasal challenge of mice with IL-33 also induced elevated airways expression of connective tissue growth factor and fibroblast growth factor receptor 4, two key facilitators of local fibrosis, again to a degree compatible with that observed in OVA-sensitized and challenged mice. Deletion of the ST2 gene, which encodes the IL-33 receptor, abrogated these fibrotic changes in the airways in the OVA surrogate. In vitro, IL-33 significantly increased the proliferation and expression of collagen III by murine lung fibroblasts. These data suggest that direct exposure of murine airways to IL-33 is able to induce local fibrotic changes, at least partially through effects of signalling through the IL-33/ST2 axis on fibroblast function and local expression of MMPs and their inhibitors, and other fibrosis-related proteins.
Introduction
Asthma causes symptoms in > 300 million people worldwide, a number expected to reach 400 million by the year 2020. 1, 2 Asthma is a chronic respiratory disease characterized by airways smooth muscle hyperresponsiveness combined with a varying degree of chronic inflammation of the airways submucosa, resulting in recurrent wheezing, chest tightness and shortness of breath. 3 These inflammatory changes, which exacerbate occlusion of the
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lumen of the airways, are potentially reversible in those patients showing satisfactory therapeutic benefit from conventional anti-asthma therapy such as inhaled corticosteroids and b 2 -adrenergic agonists, as well as oral leucotriene inhibitors. 4 Airways occlusion may, however, become irreversible at least partly because of structural changes ('remodelling') in the airways associated with the inflammation, including mucous hyperplasia, subepithelial extracellular matrix deposition, smooth muscle hypertrophy and bronchial neoangiogenesis. 5 Clearly it remains a priority fully to define the mechanisms of these irreversible changes, so that in the future their development may hopefully be pre-empted.
Interleukin-33 (IL-33) is an IL-1-like pro-inflammatory epithelial alarmin that was first discovered and named in 2005. Expression of IL-33 is increased in the airways mucosa of patients with severe asthma. It activates nuclear factor-jB, 6 mitogen-activated protein kinase and possibly other signalling pathways through its receptor ST2, resulting in increased expression of IL-4, IL-5 and IL-13 and other T helper type 2 cytokines, thereby further aggravating airways inflammation. 7, 8 Specific inhibition of IL-33 or its receptor ST2 has been reported to abrogate airways inflammation, mucus hypersecretion and airways hyper-responsiveness in murine surrogates of asthma. 9, 10 Our own previous findings have shown that direct, per-nasal application of IL-33 alone to the respiratory tract can induce typical asthmalike features in mice, including airways eosinophilic mucosal infiltration, hyperresponsiveness and neoangiogenesis. 11, 12 Recent studies indicate that IL-33 is able to exert some of these effects indirectly by activating airways mucosal group 2 innate lymphoid cells (ILC2), inducing the latter to produce T helper type 2-type cytokines. 13, 14 These findings strongly imply a pivotal role for IL-33 in the pathogenesis of the chronic airways inflammation observed in many patients with asthma.
The laying down of interstitial matrix proteins causing fibrosis and potentially irreversible airways obstruction is pathognomonic of asthma in humans. In the present study we address the hypothesis that IL-33, acting through its receptor ST2, promotes this fibrosis by direct activation of airways fibroblasts, by increasing the local production of other fibroblast growth factors and finally by upsetting the equilibrium between the local fibrinolytic activities of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs). To accomplish this we measured these changes following direct application of IL-33 to the murine respiratory tract and compared them with those observed in a conventional murine surrogate of asthma induced by ovalbumin (OVA) sensitization and challenge, the latter both in wild-type mice and those with deletion of the gene encoding the IL-33 receptor ST2.
Materials and methods

Animals
Female BALB/c mice (6-8 weeks old; Vital River Laboratory, Beijing, China) were kept in a pathogen-free environment in the Department of Laboratory Animal Sciences, Capital Medical University, Beijing, China. St2 
IL-33 challenge and OVA challenge
Murine surrogates of asthma induced by IL-33 or OVA challenge were prepared and studied as previously described. 12 Briefly, recombinant murine IL-33 (rmIL-33, 100 ng in 50 ll saline; R&D Systems, Minneapolis, MN) or saline control was administered per-nasally directly to the airways of two groups of mice daily from days 18-23 from the commencement of the experiment, then every 2 days until day 53. Further groups of mice were sensitized by intraperitoneal injection with OVA on days 0 and 12 of the experiment, then challenged per-nasally with a solution of OVA or saline control on the same days as those challenged with IL-33. Subgroups of mice in each group were killed at various, fixed time-points until day 70 (17 days after the final challenge). To further explore possible effects of the IL-33/ST2 axis on airways fibrosis, a further group of St2 À/À gene-deleted mice was also sensitized to, and challenged with, OVA or saline control and subgroups of these animals were killed and examined on days 24 and 48 (Fig. 1a) .
Lung immunohistochemistry
Immunohistochemistry was employed to quantify immunoreactivity for the most common biological markers of airways fibrosis in asthma, including collagens I, III and V, the matrix metalloproteinases MMP1, MMP2, MMP9, MMP12 and MMP13, fibroblast growth factor receptor 4 (FGFR4), connective tissue growth factor (CTGF), fibronectin and tissue inhibitor of metalloproteinase-1 (TIMP1 ethanol, then subjected to antigen retrieval by incubating in citrate or EDTA buffer. Endogenous peroxidase was quenched by incubating with 3% H 2 O 2 . The sections were then blocked with 1% bovine serum albumin (Solarbio, Beijing, China) in PBS and incubated with primary antibody overnight at 4°. After washing, the sections were incubated with appropriate secondary antibodies then washed again and incubated with a horseradish peroxidase-labelled third-layer antibody. Finally, the areas of the sections binding to the specific, first-layer antibodies were identified by colour development with 3, 3 0 -diaminobenzidine (Solarbio), then the entire sections were counterstained with haematoxylin and analysed by microscopy. Immunoreactivity was measured using a Nikon microscope (Nikon, Tokyo, Japan) connected with a computer imaging system and analysed using proprietary software (IMAGE-PRO PLUS 6.0; Media Cybernetics, Silver Spring, MD). The data were expressed as percentages of the positively stained areas in the entire lung sections as previously described.
11,12
Effects of IL-33 on the proliferation and expression of fibronectin and collagen III by murine fibroblasts (2000 cells/100 ll/well) were seeded into 96-well plates then incubated at 37°for 12 hr before adding rmIL-33 (R&D Systems, Minneapolis, MN) at final concentrations of 10, 50 or 100 ng/ml or normal saline control in a total volume of 150 ll in culture medium without fetal bovine serum (FBS). Cells were also cultured in medium containing FBS as a positive control. Cellular proliferation in the presence of saline control and in the absence of FBS was set as baseline (100% proliferation). These concentrations of IL-33 were as used in our previous study. 15 After incubation for a further 48 hr, 10 ll of CCK-8 solution was added to each well and incubation was allowed to proceed for a further 4 hr. The absorbance at 450 nm was measured with Perkin Elmer EnSpire â Multimode
Plate Reader (Waltham, MA).
A Western blotting platform was used to measure the expression of collagen III and fibronectin by murine lung fibroblasts. Cells were processed as above; briefly, MLg cells were seeded into six-well plates (10 5 cells/2 ml/well), incubated until 50% confluent then serum starved for 12 hr. Interleukin-33 was added to the plates at a final concentration of 100 ng/ml and the cells were incubated for a further 48 hr. Following incubation, 50 ll of precooled RIPA was added to each well with thorough shaking on ice until the cells were fully lysed. The lysates were then centifuged at 13 200 g for 20 min at 4°, then the supernatants were gently aspirated and transferred to a fresh precooled microcentrifuge tube on ice. The 8-ll aliquots of the lysates were mixed with 2 ll of protein loading buffer (10% sodium dodecyl sulphate (SDS), 5% 2- mercaptoethanol, 50% glycerol and 0Á5% bromophenol blue in 250 mM Tris-HCl, pH 6Á8). After heating to 95°f or 10 min, the proteins in the lysate were separated using 10% SDS-polyacrylamide gel electrophoresis. Separated proteins in the gels were electrophoretically transferred to a nitrocellulose membrane (250 mA, 2 hr). The membrane was then blocked with 5% skimmed milk in PBS containing 0Á05% Tween 20 (PBS-T buffer) for 1 hr at room temperature. After washing the membrane with PBS-T, it was incubated with the same primary antibodies as used in the immunohistochemical analysis above against collagen III (1 : 1000; Abcam, Cambridge, UK) and fibronectin (1 : 1000; Abcam) and an anti-b-actin antibody (1 : 2000; Abcam) to serve as a loading control diluted in PBS-T containing 0Á25% BSA and the membrane was incubated overnight at 4°. After washing the membrane with PBS-T again, the bound antibodies were detected by staining with a 1 : 10 000 dilution of goat anti-mouse or anti-rabbit IRDye (according to the species of origin of the primary antibody; LI-COR Biosciences, Lincoln, NE) in 10 ml of PBS-T buffer for 1 hr at room temperature. After final washing, the membranes were imaged and analysed using an Odyssey infrared imaging system (LI-COR Biosciences, Lincoln, NE).
Statistical analysis
All data were processed using GRAPHPAD PRISM 7.0 software (GraphPad, San Diego, CA). Differences between experimental groups were analysed using one-way or two-way analysis of variance followed by a Bonferroni post test or the Student's unpaired t-test. For all tests, P-values < 0Á05 were considered significant.
Results
IL-33 increases lung extracellular matrix protein deposition
Compared with saline, repeated, per-nasal challenge of the murine airways with IL-33 alone resulted in deposition of extracellular matrix proteins in and around the airways, with distinct time courses. Significantly elevated expression of immunoreactivity for collagen I was apparent from day 48 and persisted until the end of the study (day 70, Fig. 1b,c) . Significantly elevated collagen III/V immunoreactivity was apparent from day 36 and again persisted until the end of the study (see Supplementary material, Figs S1 and S2). OVA-sensitized and OVA-challenged mice showed similar changes, except that the onset of elevated expression of immunoreactivity for collagens I and III was later than with IL-33 challenge ( Fig. 1 and see Supplementary material,  Fig. S1 ). Interleukin-33 challenge also promoted the deposition of fibronectin in and around the murine airways, although this effect was more delayed and less extensive than that associated with OVA challenge (Fig. 2) . 
IL-33 induces elevated CTGF and FGFR4 expression
Global immunoreactivity for CTGF was significantly elevated in and around the airways of the IL-33-challenged mice, with a transient time-course similar to that observed in association with OVA challenge except that, in the latter case, CTGF immunoreactivity was significantly elevated somewhat earlier (from day 20) (Fig. 3) . Compared with saline, IL-33 challenge also induced significantly elevated expression of FGFR4 immunoreactivity commencing from day 24 and persisting until the end of the experiment. A similar time-course of elevated expression on FGFR4 was observed following OVA challenge, although the extent of the changes was much more obvious with this stimulus (Fig. 4) .
IL-33 regulates expression of MMPs and TIMPs
Per-nasal challenge of the airways of the mice with IL-33 alone was also sufficient transiently and significantly to elevate expression of immunoreactivity for MMP1 and MMP13 in and around the airways between days 36 and 54, a time-course of elevation similar to that observed following OVA challenge ( airways MMP expression was observed in the case of MMP2, where IL-33 challenge did not significantly alter MMP2 expression whereas OVA challenge caused a significant increase in the expression of MMP2 immunoreactivity apparent from day 24, which persisted until the end of the experiment (Fig. 7) . Finally, both IL-33 and OVA challenge resulted in a transient, significant elevation of the expression of immunoreactivity for TIMP1 apparent from day 36 (Fig. 8) .
IL-33 promotes fibroblast proliferation and collagen production
In vitro, rmIL-33 significantly promoted the proliferation of murine lung fibroblasts (Fig. 9) . Furthermore, IL-33 stimulation resulted in elevated expression of collagen III by these cells, although we observed no effect of IL-33 on the production of fibronectin at the concentration employed.
Effects of the IL-33/ST2 axis on pulmonary fibrosis
To further clarify the possible contribution of IL-33/ST2 axis signalling to airways fibrosis in this animal asthma surrogate, we repeated the challenge experiments with OVA in St2 À/À mice. Knockdown of the ST2 gene significantly attenuated the effects of OVA challenge in increasing the expression of immunoreactivity for fibronectin, CTGF, FGFR4, MMP2, MMP9 and MMP12 in the airways compared with OVA-challenged wild-type mice ( Fig. 10 and see Supplementary material, Fig. S5 ). 
Discussion
Previous studies have strongly implicated IL-33 in playing a key role in the pathogenesis of the airways mucosal inflammation that typically accompanies human asthma. [7] [8] [9] [10] [11] [12] In our own previous studies we showed that direct, per-nasal application of IL-33 alone to the murine airway is sufficient to cause asthma-like inflammation, including subepithelial deposition of collagens. 11, 12 We have here greatly extended these observations to focus on the effects of IL-33 on the pro-fibrotic inflammatory milieu in the airways. We have shown that direct, per-nasal administration of IL-33 to the airways alters the balance of expression of MMPs and their inhibitors and also promotes the expression of key, profibrotic proteins acting on fibroblasts, including CTGF and FGFR4. To further underline the relevance of these effects of IL-33 in asthma, we have shown that these IL-33-induced changes were broadly, although not completely, comparable with those observed in a more 'classical' murine surrogate of asthma employing OVA sensitization and challenge. Furthermore, these effects of IL-33 were significantly, but not completely, abrogated in IL-33-receptor-deficient (St2 À/À ) mice sensitized and challenged with OVA. IL-33 directly induced proliferation and collagen production by lung fibroblasts in vitro. Taken together, our data provide further, strong support of the hypothesis that activation of the IL-33/ST2 signalling pathway plays a key role in the development of airways fibrosis. Recent studies have similarly implicated IL-33 or its receptor ST2 in the pathogenesis of fibrosis in various organs such as the lung parenchyma, the liver, the heart and the skin. [16] [17] [18] [19] Interleukin-33 transgenic mice develop pulmonary fibrosis. 20 In a bleomycin-induced surrogate of pulmonary fibrosis, 20 administration of exogenous IL-33 amplified fibrosis and collagen synthesis, possibly through acting on macrophages and ILC2 cells, the latter cells being sources of production of other pro-fibrotic cytokines such as transforming growth factor-b (TGF-b) and IL-13. Such mechanisms may partly explain why, in the present study, IL-33 did not directly induce the synthesis of fibronectin by murine fibroblasts in vitro, whereas per-nasal administration of IL-33 in vivo did enhance the expression of fibronectin in the murine airways in a manner compatible with that observed in the OVA-challenged mice. This and other indirect effects of IL-33 in vivo might result from its actions on cells other than fibroblasts causing the release of additional mediators, including ILC2s, macrophages and mast cells. 21, 22 In the present study, IL-33-treated mice developed elevated airways expression of FGFR4 and CTGF, two important factors involved in fibrosis. CTGF, a member of the CNN protein family, plays an important role in wound healing and tissue repair, and has been reported to act synergistically with TGF-b in sustaining fibrosis. 23 Moreover, previous studies have shown that over-expression of CTGF promotes fibrosis in a variety of tissues or organs, or conversely that blockade or knockdown of CTGF can significantly reduce this. [24] [25] [26] [27] FGFR4 signalling has been reported to synergize with that of TGF-b together to activate injury-primed renal fibroblasts. 28 Our previous data demonstrate that IL-33 promotes the expression of TGF-b and bFGF. 11 It is reasonable to postulate, therefore, that IL-33 acts on the one hand to promote the synthesis of FGF and TGF-b, and on the other hand to increase the expression of FGFR4, both of which promote fibroblast collagen synthesis.
Both MMPs and TIMPs play an important role in airways remodelling. 29 MMPs are capable of degrading extracellular matrix proteins during inflammation to promote remodelling, whereas TIMPs are natural inhibitors of MMPs. [30] [31] [32] Hence, the equilibrium of expression of MMPs and TIMPs probably determines the degree of deposition of extracellular matrix. Our present data clearly show that exogenous administration of IL-33 can alter the expression of MMPs and TIMPs simultaneously in the airways. Knockdown of the St2 gene significantly reduced collagen deposition around the airways in the OVA-challenged mice concomitantly with significantly reduced expression of MMPs. This further underlines the specificity of the effects of IL-33 in airways remodelling in influencing MMP expression in the airways inflammatory process associated with asthma. It is worth noting again, however, that IL-33 challenge alone did not precisely recapitulate the effects of OVA sensitization and challenge because, for example, under the particular conditions of our experiments it did not result in elevation of MMP2 expression. Although we cannot discern the precise explanation for this, we speculate that one possible explanation is that, being a murine surrogate of 'allergic asthma', the airways inflammation induced in the OVA sensitization/challenge model is IgE-dependent, whereas we previously detected no role for IgE in the airways inflammation induced by direct IL-33 challenge. 11 In this regard, it is interesting that deletion of the St2 gene partially but significantly reduced OVA-induced MMP2 expression, suggesting that the IL-33/ST2 axis does contribute, at least partially and indirectly, to the production of MMP2 in asthma.
The broadly contemporaneous profile of development of expression of MMP1, MMP9 and MMP13 is potentially of mechanistic significance because these MMPs can activate each other, [33] [34] [35] although one study 36 has suggested an inhibitory role for MMP9 in bleomycin-induced pulmonary fibrosis, so that the possibility of a protective role for some of these proteinases in the induction of fibrosis must also be considered. On the other hand, we demonstrate spatial and temporal differences in the expression of some of these proteins, for example the In summary, IL-33 alone can cause airways submucosal fibrotic changes very similar to those observed in conventional surrogates of asthmatic mucosal inflammation triggered by IgE-dependent mechanisms, suggesting that IL-33 plays a similarly important role in the pathogenesis of the airways submucosal fibrotic changes that characterize human asthma. Our data also suggest that these effects of IL-33 reflect not only a direct action on airways fibroblasts but also indirect effects mediated through other cells and mediators within the airways mucosa. Our ongoing studies are directed at further clarification of these mechanisms.
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